Clinical Trial

Risk Factors, Incidence, and Progression of Lymphedema Among Men With Prostate Cancer. The AWARE Cohort

Study acronym: AWARE
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this observational study is to examine the development and impact of lymphedema in men treated for prostate cancer. Lymphedema is swelling caused by damage to the lymphatic system and may develop after surgery with lymph node removal or after radiotherapy. The main questions it aims to answer are: How many men develop lower limb lymphedema after prostate cancer treatment? Which men are at highest risk of developing lymphedema? How does lymphedema affect quality of life? Participants will attend follow-up visits every three months for 18 months at one of three Danish hospital sites: Rigshospitalet, Herlev-Gentofte Hospital, or Zealand University Hospital. At each visit, participants will undergo examinations for signs of lymphedema and complete questionnaires about symptoms, quality of life, and daily functioning. Participants who develop signs of lymphedema during the study will be advised to seek assessment and treatment from the hospital's lymphedema therapist.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-05-19.
Trial Details
NCT Number NCT07607431
Lead Sponsor Rigshospitalet, Denmark
Conditions Prostate Cancer, Lower Limb Lymphedema
Enrollment 214 participants
Start Date 2024-02-02
Primary Completion 2026-10-31 (estimated)
Study Completion 2026-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-15